OVID Plunges, VNDA's Hetlioz Scores Another FDA Nod,

OVID Plunges, VNDA's Hetlioz Scores Another FDA Nod, Auris Investors Smile Ear To Ear

RTTNews

Published 02 Dec 2020

Today's Daily Dose brings you news about OVID'S Angelman syndrome trial failure, the FDA expanding approval of Vanda's Hetlioz to Smith-Magenis Syndrome, the 455% jump in stock price of Auris Medical, Histogen's phase Ib/IIa clinical trial results of HST-001 in male patients with androgenic alopecia, and Regeneron's plans to test delivery of Covid-19 antibody cocktail via a gene therapy platform.

Full Article

OVID Plunges, VNDA's Hetlioz Scores Another FDA Nod, Auris Investors Smile Ear To Ear

OVID Plunges, VNDA's Hetlioz Scores Another FDA Nod, Auris Investors Smile Ear To Ear

You might like